• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy.

作者信息

Parkinson D R

机构信息

Department of Clinical Immunology and Biological Therapy, M. D. Anderson Hospital, Houston, Texas.

出版信息

Drug Saf. 1990;5 Suppl 1:75-83. doi: 10.2165/00002018-199000051-00012.

DOI:10.2165/00002018-199000051-00012
PMID:2182067
Abstract

Cytokines are the protein products of cells which regulate proliferation, differentiation and functional activation. The potent biological properties of these proteins have led to their introduction into clinical medicine as pharmacological agents. The cytokines most studied to date include the interferons, some of the interleukins and the haematopoietic growth factors. Although they have most often been studied in cancer patients, widespread application of these agents in many other fields is likely. Despite the fact that these are recombinant proteins of defined sequence, their intricate biology complicates clinical investigation. Proteins may be of native or mutated sequence and their degree of glycosylation is further affected by the expression system used for their production. Furthermore, although these cytokines interact with specific cell surface receptors, pleotropic biological consequences may follow from the interaction of ligand with receptors. As a consequence, significant dose and schedule dependency exists for these agents, and the particular administration regimen as well as the route of delivery may greatly affect the biological and clinical characteristics of these drugs. Thus, direct comparisons of different cytokine problems may be difficult. These issues reinforce the need for increased biological understanding of cytokines if these agents are to be used rationally and safely in clinical medicine.

摘要

相似文献

1
Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy.
Drug Saf. 1990;5 Suppl 1:75-83. doi: 10.2165/00002018-199000051-00012.
2
Biological standardization of cytokines.细胞因子的生物学标准化
Dev Biol Stand. 1988;69:199-206.
3
[Cytokines in the clinic].[临床中的细胞因子]
Helv Chir Acta. 1990 Jan;56(5):683-8.
4
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].干扰素和白细胞介素与放疗联合的抗肿瘤作用。第一部分:免疫学基础
Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x.
5
TRAIL receptor signalling and modulation: Are we on the right TRAIL?肿瘤坏死因子相关凋亡诱导配体(TRAIL)受体信号传导与调节:我们是否选对了TRAIL?
Cancer Treat Rev. 2009 May;35(3):280-8. doi: 10.1016/j.ctrv.2008.11.006. Epub 2008 Dec 30.
6
[Cytokines and their receptors networks: biology and therapeutic possibilities].[细胞因子及其受体网络:生物学与治疗潜力]
Pediatrie. 1989;44(7):531-8.
7
Radioprotection and therapy of radiation injury with cytokines.
Prog Clin Biol Res. 1990;352:471-8.
8
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
9
Colony-stimulating factors for the management of neutropenia in cancer patients.用于癌症患者中性粒细胞减少症管理的集落刺激因子。
Drugs. 2002;62 Suppl 1:1-15. doi: 10.2165/00003495-200262001-00001.
10
Lymphokines and cytokines.
Cancer Chemother Biol Response Modif. 1987;9:432-53.

本文引用的文献

1
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.对转移性癌症患者进行自体淋巴因子激活的杀伤细胞和重组白细胞介素-2全身给药的观察。
N Engl J Med. 1985 Dec 5;313(23):1485-92. doi: 10.1056/NEJM198512053132327.
2
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.重组人粒细胞巨噬细胞集落刺激因子对骨髓增生异常综合征患者的影响。
N Engl J Med. 1987 Dec 17;317(25):1545-52. doi: 10.1056/NEJM198712173172501.
3
Administration of slowly released recombinant interleukin 2. Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells.
缓慢释放重组白细胞介素2的给药。增强过继性免疫疗法与淋巴因子激活的杀伤(LAK)细胞的疗效。
J Immunol Methods. 1986 Jul 11;91(1):21-7. doi: 10.1016/0022-1759(86)90097-9.
4
Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.利用淋巴因子激活的杀伤细胞和重组白细胞介素-2进行癌症的过继性免疫治疗。
Important Adv Oncol. 1986:55-91.
5
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.循环肿瘤坏死因子(TNFα)的诱导作为癌症患者对白介素-2(IL-2)发热反应的机制。
J Clin Immunol. 1988 Nov;8(6):426-36. doi: 10.1007/BF00916947.
6
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.白细胞介素-2和淋巴因子激活的杀伤细胞治疗后出现甲状腺功能减退。
N Engl J Med. 1988 Jun 16;318(24):1557-63. doi: 10.1056/NEJM198806163182401.
7
Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.白细胞介素-2输注剂量和持续时间对毒性及免疫调节的影响。
J Clin Oncol. 1988 Apr;6(4):669-78. doi: 10.1200/JCO.1988.6.4.669.
8
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.采用白细胞介素-2和淋巴因子激活的杀伤细胞治疗转移性肾癌。一项II期临床试验。
Ann Intern Med. 1988 Apr;108(4):518-23. doi: 10.7326/0003-4819-108-4-518.
9
The determination of an immunologically active dose of interferon-gamma in patients with melanoma.
J Clin Oncol. 1988 Mar;6(3):434-45. doi: 10.1200/JCO.1988.6.3.434.
10
Interleukin-2 in cancer therapy.白细胞介素-2在癌症治疗中的应用。
Semin Oncol. 1988 Dec;15(6 Suppl 6):10-26.